[1] World Health Organization Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance[J]. Pediatria i Medycyna Rodzinna, 2020, 16(1): 9-26. [2] National Health Commission, National Administration of Traditional Chinese Medicine.Guidelines for the diagnosis and treatment of novel coronavirus pneumonia (trial version sixth)[J]. Chinese Journal of Viral Diseases(中国病毒病杂志), 2020,10(2): 81-85. [3] Vogel M, Rockstroh JK.Safety of lopinavir/ritonavir for the treatment of HIV-infection[J]. Expert Opin Drug Saf, 2005, 4(3): 403-420. [4] Chen L, Li HL, Liu X, et al.The Data-Mining of ADR Signals for Lopinavir/ritonavir Based on US FAERS Database[J/]. Adverse Drug Reactions Journal(药物不良反应杂志),2020, 22(00):E002-E002. [5] Fu Y, Li XP, Yu ZY, et al.Assessment of the causality of severe diarrhea caused by paclitaxel in case reports by using Naranjo's assessment scale[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(20): 2150-2153. [6] National Cancer Institute(NCI). Common terminolgy criteria for adverse events(CTCAE)v4.03 [EB/OL].(2017-08-01)[2010-06-14].https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_5x7. pdf. [7] Cai HD.Safety application of novel coronavirus pneumonia antiviral drugs[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(2): 95-102. [8] Ng J, Chiu YL, Awni W, et al.Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants[J]. J Clin Pharmacol, 2012, 52(8): 1248-1254 [9] Chu CM,Cheng VC,Hung IF,et al.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J].Thorax, 2004, 59(3): 252-256. [10] Nukoolkarn V, Lee VS, Malaisree M, et al.Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors[J]. Journal of Theoretical Biology, 2008, 254(4): 861-867. [11] Gralinski LE, Menachery VD.Return of the Coronavirus: 2019-nCoV[J]. Viruses, 2020, 12(2):135-142. [12] Jiang H, Deng HF, Wang Y, et al.The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies[J]. Chinese Journal of Emergency Medicine(中华急诊医学杂志), 2020, 29(2): 182-186. [13] Lim J,Jeon S,Shin HY,et al.Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea:the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR[J]. J Korean Med Sci, 2020, 35(6): e79. [14] Cao B,Wang Y,Wen D,et al.A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19[J].N Engl J Med, 2020, 382(19): 1787-1799. [15] Li Y, Cui YH, Pan PH, et al.Research progress on drug therapy of COVID-19[J].Chinese Journal of Infection Control(中国感染控制杂志), 2020, 19(10): 945-950. [16] AbbVie Deutschland GmbH&Co.KG. Instructions for Lopinavir and Litonavir Tab lets (洛匹那韦利托那韦片说明书) [EB/OL].(2015-03-27)[2020-02-20]. http://drugs.dxy.cn/drug/149903.htm. [17] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet, 2020, 395(10223): 497-506. [18] Xuan ZX, Zhang GB, Ye XL, et al.Cause analysis of liver injury in patients infected by novel coronavirus and suggestion of drug monitoring[J]. Chinese Pharmacological Bulletin(中国药理学通报),2020 ,36(4): 591-592. [19] Nijland HM, L'homme RF, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets[J]. AIDS, 2008, 22(8): 931-935. [20] Walmsley S, Bernstein B, King M, et al.Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection[J].N Engl J Med, 2002, 346(26): 2039-2046. [21] Chong YP, Song JY, Seo YB, et al.Antiviral treatment guidelines for Middle East respiratory syndrome[J].Infect Chemother, 2015, 47(3): 212-222. [22] Yang MY, Gao YY, Zou YJ, et al.Pharmacological recommendations on the off-label use of lopinavir/ritonavir for treatment of coronavirus disease 2019[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2020, 40(6): 617-621. |